# A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville

> **NCT00790777** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 72 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Paliperidone ER

## Key facts

- **NCT ID:** NCT00790777
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2011-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00790777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00790777, "A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00790777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*